These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. New delivery systems in contraception: vaginal rings. Johansson ED; Sitruk-Ware R Am J Obstet Gynecol; 2004 Apr; 190(4 Suppl):S54-9. PubMed ID: 15105799 [TBL] [Abstract][Full Text] [Related]
24. The ring plus project: safety and acceptability of vaginal rings that protect women from unintended pregnancy. Schurmans C; De Baetselier I; Kestelyn E; Jespers V; Delvaux T; Agaba SK; van Loen H; Menten J; van de Wijgert J; Crucitti T; BMC Public Health; 2015 Apr; 15():348. PubMed ID: 25880636 [TBL] [Abstract][Full Text] [Related]
25. Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections. Friend DR Drug Deliv Transl Res; 2011 Jun; 1(3):185-93. PubMed ID: 25788239 [TBL] [Abstract][Full Text] [Related]
26. A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use. Kestelyn E; Agaba S; Van Nuil JI; Uwineza M; Umulisa MM; Mwambarangwe L; Ndagijimana JC; De Baetselier I; Buyze J; Delvaux T; Crucitti T; Jespers V; van de Wijgert JHHM; PLoS One; 2018; 13(6):e0197572. PubMed ID: 29856848 [TBL] [Abstract][Full Text] [Related]
27. Development of polyether urethane intravaginal rings for the sustained delivery of hydroxychloroquine. Chen Y; Traore YL; Li A; Fowke KR; Ho EA Drug Des Devel Ther; 2014; 8():1801-15. PubMed ID: 25336923 [TBL] [Abstract][Full Text] [Related]
28. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138 [TBL] [Abstract][Full Text] [Related]
29. Advances in microbicide vaginal rings. Malcolm RK; Edwards KL; Kiser P; Romano J; Smith TJ Antiviral Res; 2010 Dec; 88 Suppl 1():S30-9. PubMed ID: 21109066 [TBL] [Abstract][Full Text] [Related]
30. Development of Hormonal Intravaginal Rings: Technology and Challenges. Rafiei F; Tabesh H; Farzad S; Farzaneh F; Rezaei M; Hosseinzade F; Mottaghy K Geburtshilfe Frauenheilkd; 2021 Jul; 81(7):789-806. PubMed ID: 34276064 [TBL] [Abstract][Full Text] [Related]
31. Sustained release of microbicides by newly engineered vaginal rings. Saxena BB; Han YA; Fu D; Rathnam P; Singh M; Laurence J; Lerner S AIDS; 2009 May; 23(8):917-22. PubMed ID: 19381077 [TBL] [Abstract][Full Text] [Related]
32. [Preparation and release mechanism of gestodene reservoir-type intravaginal rings]. Li CX; Wang YK; Ning MY Yao Xue Xue Bao; 2014 Mar; 49(3):399-405. PubMed ID: 24961114 [TBL] [Abstract][Full Text] [Related]
33. User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa. Sahin-Hodoglugil NN; Montgomery E; Kacanek D; Morar N; Mtetwa S; Nkala B; Philip J; Ramjee G; Cheng H; van der Straten A; The Mira Team AIDS Care; 2011 Aug; 23(8):1026-34. PubMed ID: 21480005 [TBL] [Abstract][Full Text] [Related]
34. Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures. Srinivasan P; Moss JA; Gunawardana M; Churchman SA; Yang F; Dinh CT; Mitchell JM; Zhang J; Fanter R; Miller CS; Butkyavichene I; McNicholl JM; Smith TJ; Baum MM; Smith JM PLoS One; 2016; 11(6):e0157061. PubMed ID: 27275923 [TBL] [Abstract][Full Text] [Related]
35. Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design. Guthrie KM; Dunsiger S; Vargas SE; Fava JL; Shaw JG; Rosen RK; Kiser PF; Kojic EM; Friend DR; Katz DF AIDS Res Hum Retroviruses; 2016; 32(10-11):1022-1030. PubMed ID: 26942455 [TBL] [Abstract][Full Text] [Related]
36. Compartmental transport model of microbicide delivery by an intravaginal ring. Geonnotti AR; Katz DF J Pharm Sci; 2010 Aug; 99(8):3514-21. PubMed ID: 20222027 [TBL] [Abstract][Full Text] [Related]
37. Adolescents, sex and injecting drug use: risks for HIV infection. Barnard M; McKeganey N AIDS Care; 1990; 2(2):103-16. PubMed ID: 2085532 [TBL] [Abstract][Full Text] [Related]
38. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. Keller MJ; Mesquita PM; Marzinke MA; Teller R; Espinoza L; Atrio JM; Lo Y; Frank B; Srinivasan S; Fredricks DN; Rabe L; Anderson PL; Hendrix CW; Kiser PF; Herold BC AIDS; 2016 Mar; 30(5):743-51. PubMed ID: 26605514 [TBL] [Abstract][Full Text] [Related]
39. The hormonal ring. A new contraceptive gains acceptance. Hardy EE; Reyes Q; Gomez F; Portes-carrasco R; Faundes A IDRC Rep; 1984 Jul; 13(2):11. PubMed ID: 12313242 [TBL] [Abstract][Full Text] [Related]
40. A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. Fetherston SM; Boyd P; McCoy CF; McBride MC; Edwards KL; Ampofo S; Malcolm RK Eur J Pharm Sci; 2013 Feb; 48(3):406-15. PubMed ID: 23266465 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]